96 results
Page 3 of 5
8-K
69v7dpbfw
7 Apr 20
Departure of Directors or Certain Officers
8:01am
8-K
EX-10.1
63wncat4fk4x4 tuf4w
12 Mar 20
Sientra Announces $60 Million Convertible Notes Investment from
4:40pm
8-K
EX-99.1
lk9l tn2yge
13 Jan 20
Sientra Announces Preliminary Unaudited 4Q19 Net Sales
5:25pm
8-K
EX-10.1
y7xjjlu
7 Nov 19
Entry into a Material Definitive Agreement
4:38pm
8-K
EX-10.2
0yk4dgydblda7y
7 Nov 19
Entry into a Material Definitive Agreement
4:38pm
8-K/A
EX-99.1
858bgacff9cjbf
9 Aug 19
Sientra Reports Second Quarter 2019 Financial Results
4:25pm
8-K
EX-99.1
eu5d2j dcgh
8 Aug 19
Sientra Reports Second Quarter 2019 Financial Results
4:21pm
8-K
EX-1.1
7ypllmy 82ppnzmo
5 Jun 19
Sientra Commences Public Offering of Common Stock
4:10pm
424B5
acwxzupko1wbyu yz95
5 Jun 19
Prospectus supplement for primary offering
4:03pm
424B5
ecikfc4 97qi0y4xe
3 Jun 19
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
kcy l5uw392au8wk
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
8-K
EX-99.1
zhi89m849bcyjdvd
12 Mar 19
Sientra Reports Fourth Quarter and Full Year 2018 Financial Results
4:31pm